268 related articles for article (PubMed ID: 27899372)
1. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.
van Daalen EE; Rizzo R; Kronbichler A; Wolterbeek R; Bruijn JA; Jayne DR; Bajema IM; Rahmattulla C
Ann Rheum Dis; 2017 Jun; 76(6):1064-1069. PubMed ID: 27899372
[TBL] [Abstract][Full Text] [Related]
2. Antineutrophil cytoplasmic antibody-associated vasculitis and malignancy.
Wester Trejo MAC; Bajema IM; van Daalen EE
Curr Opin Rheumatol; 2018 Jan; 30(1):44-49. PubMed ID: 28957961
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Malignancies in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Diagnosed Between 1991 and 2013.
Rahmattulla C; Berden AE; Wakker SC; Reinders ME; Hagen EC; Wolterbeek R; Bruijn JA; Bajema IM
Arthritis Rheumatol; 2015 Dec; 67(12):3270-8. PubMed ID: 26246307
[TBL] [Abstract][Full Text] [Related]
4. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.
Heijl C; Harper L; Flossmann O; Stücker I; Scott DG; Watts RA; Höglund P; Westman K; Mahr A;
Ann Rheum Dis; 2011 Aug; 70(8):1415-21. PubMed ID: 21616914
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
6. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
[TBL] [Abstract][Full Text] [Related]
7. Malignancy is increased in patients with antineutrophil cytoplasmic antibody-associated vasculitis in China.
Han XY; Li ZY; Zhao MH; Little MA; Chen M
Arthritis Res Ther; 2024 May; 26(1):113. PubMed ID: 38822382
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series.
Caroti L; Cirami CL; Di Maria L; Larti A; Carta P; Dervishi E; Farsetti S; Tsalouchos A; Novelli L; Minetti EE
BMC Nephrol; 2019 May; 20(1):162. PubMed ID: 31088509
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
10. The complications of vasculitis and its treatment.
King C; Harper L; Little M
Best Pract Res Clin Rheumatol; 2018 Feb; 32(1):125-136. PubMed ID: 30526892
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Rituximab- Versus Cyclophosphamide-Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the Risk of Kidney Failure and Mortality.
Wallace ZS; Fu X; Cook C; Ahola C; Williams Z; Doliner B; Hanberg JS; Stone JH; Zhang Y; Choi HK
Arthritis Rheumatol; 2023 Sep; 75(9):1599-1607. PubMed ID: 37011036
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Malignancy Prior to Antineutrophil Cytoplasmic Antibody-associated Vasculitis Compared to the General Population.
van Daalen EE; Rahmattulla C; Wolterbeek R; Bruijn JA; Bajema IM
J Rheumatol; 2017 Mar; 44(3):314-318. PubMed ID: 28089971
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for ANCA-associated vasculitis in the setting of severe infection.
Gregersen JW; Chaudhry A; Jayne DR
Scand J Rheumatol; 2013; 42(3):207-10. PubMed ID: 23286789
[TBL] [Abstract][Full Text] [Related]
14. Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the US.
James KE; Xiao R; Merkel PA; Weiss PF
Arthritis Care Res (Hoboken); 2017 Sep; 69(9):1377-1383. PubMed ID: 27813340
[TBL] [Abstract][Full Text] [Related]
15. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis.
Faurschou M; Mellemkjaer L; Voss A; Keller KK; Hansen IT; Baslund B
Rheumatology (Oxford); 2015 Aug; 54(8):1345-50. PubMed ID: 25234661
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.
McAdoo SP; Medjeral-Thomas N; Gopaluni S; Tanna A; Mansfield N; Galliford J; Griffith M; Levy J; Cairns TD; Jayne D; Salama AD; Pusey CD
Nephrol Dial Transplant; 2019 Jan; 34(1):63-73. PubMed ID: 29462348
[TBL] [Abstract][Full Text] [Related]
17. [Recommendations on the use of rituximab for ANCA-associated vasculitis].
Gause AM; Rubbert-Roth A;
Z Rheumatol; 2014 Apr; 73(3):287-9. PubMed ID: 27039911
[TBL] [Abstract][Full Text] [Related]
18. Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Cortazar FB; Pendergraft WF; Wenger J; Owens CT; Laliberte K; Niles JL
Arthritis Rheumatol; 2017 May; 69(5):1045-1053. PubMed ID: 28029751
[TBL] [Abstract][Full Text] [Related]
19. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
20. Brief Report: Menopause and Primary Ovarian Insufficiency in Women Treated for Antineutrophil Cytoplasmic Antibody-Associated Vasculitides.
Tuin J; Sanders JS; van Beek AP; Hoek A; Stegeman CA
Arthritis Rheumatol; 2016 Apr; 68(4):986-92. PubMed ID: 27023359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
